BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15925360)

  • 1. Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor.
    Meini S; Catalani C; Bellucci F; Cucchi P; Giuliani S; Zappitelli S; Rotondaro L; Pasqui F; Guidi A; Altamura M; Giolitti A; Maggi CA
    Eur J Pharmacol; 2005 Jun; 516(2):104-11. PubMed ID: 15925360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological evaluation of alpha and beta human tachykinin NK(2) receptor splice variants expressed in CHO cells.
    Bellucci F; Meini S; Catalioto RM; Catalani C; Giuliani S; Quartara L; Giolitti A; Faiella A; Rotondaro L; Candenas ML; Pinto FM; Maggi CA
    Eur J Pharmacol; 2004 Sep; 499(3):229-38. PubMed ID: 15381044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of aromatic residues in transmembrane segments V to VII for binding of peptide and nonpeptide antagonists to the human tachykinin NK(2) receptor.
    Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Ferrer C; Giolitti A; Guelfi M; Rotondaro L; Warner FJ; Maggi CA
    J Pharmacol Exp Ther; 1999 Aug; 290(2):487-95. PubMed ID: 10411554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutagenesis at the human tachykinin NK(2) receptor to define the binding site of a novel class of antagonists.
    Meini S; Bellucci F; Catalani C; Cucchi P; Patacchini R; Rotondaro L; Altamura M; Giuliani S; Giolitti A; Maggi CA
    Eur J Pharmacol; 2004 Mar; 488(1-3):61-9. PubMed ID: 15044036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
    Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
    Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
    Meini S; Bellucci F; Catalani C; Cucchi P; Giolitti A; Santicioli P; Giuliani S
    J Pharmacol Exp Ther; 2009 May; 329(2):486-95. PubMed ID: 19218528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tachykinin NK2 receptors: characterization in the rat small intestine by the use of a peptide agonist and a nonpeptide antagonist as radioligands.
    Renzetti AR; Criscuoli M; Maggi CA
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):139-44. PubMed ID: 9228201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defects of tyrosine289phenylalanine mutation on binding and functional properties of the human tachykinin NK2 receptor stably expressed in chinese hamster ovary cells.
    Renzetti AR; Catalioto RM; Carloni C; Criscuoli M; Cucchi P; Giolitti A; Zappitelli S; Rotondaro L; Maggi CA
    Biochem Pharmacol; 1999 Apr; 57(8):899-906. PubMed ID: 10086323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.
    Gether U; Yokota Y; Emonds-Alt X; Brelière JC; Lowe JA; Snider RM; Nakanishi S; Schwartz TW
    Proc Natl Acad Sci U S A; 1993 Jul; 90(13):6194-8. PubMed ID: 7687062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of [3H]MEN 11420, a novel glycosylated peptide antagonist radioligand of the tachykinin NK2 receptor.
    Renzetti AR; Catalioto RM; Criscuoli M; Cucchi P; Lippi A; Guelfi M; Quartara L; Maggi CA
    Biochem Biophys Res Commun; 1998 Jul; 248(1):78-82. PubMed ID: 9675089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEN 10,627, a novel polycyclic peptide antagonist of tachykinin NK2 receptors.
    Maggi CA; Astolfi M; Giuliani S; Goso C; Manzini S; Meini S; Patacchini R; Pavone V; Pedone C; Quartara L
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1489-500. PubMed ID: 7996462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
    Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
    Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the [125I]-neurokinin A binding site in the circular muscle of human colon.
    Warner FJ; Comis A; Miller RC; Burcher E
    Br J Pharmacol; 1999 Jul; 127(5):1105-10. PubMed ID: 10455255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GR159897, a potent non-peptide antagonist at tachykinin NK2 receptors.
    Beresford IJ; Sheldrick RL; Ball DI; Turpin MP; Walsh DM; Hawcock AB; Coleman RA; Hagan RM; Tyers MB
    Eur J Pharmacol; 1995 Jan; 272(2-3):241-8. PubMed ID: 7713168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of ibodutant at NK(2) receptor in human colon.
    Santicioli P; Meini S; Giuliani S; Catalani C; Bechi P; Riccadonna S; Ringressi MN; Maggi CA
    Eur J Pharmacol; 2013 Feb; 702(1-3):32-7. PubMed ID: 23376417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists.
    Smith PW; Cooper AW; Bell R; Beresford IJ; Gore PM; McElroy AB; Pritchard JM; Saez V; Taylor NR; Sheldrick RL
    J Med Chem; 1995 Sep; 38(19):3772-9. PubMed ID: 7562907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent coupling of the human tachykinin NK2 receptor to phospholipases C and A2 in transfected Chinese hamster ovary cells.
    Catalioto RM; Cucchi P; Renzetti AR; Criscuoli M; Maggi CA
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Oct; 358(4):395-403. PubMed ID: 9826060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
    Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.
    Chung FZ; Wu LH; Vartanian MA; Watling KJ; Guard S; Woodruff GN; Oxender DL
    Biochem Biophys Res Commun; 1994 Feb; 198(3):967-72. PubMed ID: 8117304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.